Eli Lilly to Buy Psychedelics Company AtaiBeckley for $2.8 Billion

Eli Lilly announced Thursday it's acquiring AtaiBeckley Inc., a clinical-stage biopharmaceutical company, for $2.8 billion upfront, according to a joint statement from both companies distributed via PR Newswire. The deal could grow by up to $1 billion more — roughly $3.8 billion total — if AtaiBeckley hits certain development and regulatory milestones, per the companies' statement.

Lilly is paying $6.75 per share in cash. That's 26% above AtaiBeckley's Wednesday close of $5.36, CNBC reported. The purchase price also represents about a 40% premium to AtaiBeckley's 30-day volume-weighted average trading price through July 15, 2026, according to the companies' statement. Shares of AtaiBeckley, which trades on the Nasdaq under the ticker ATAI, jumped more than 30% in premarket trading after the announcement.

What Lilly Is Actually Buying

The headline asset is BPL-003, also known as mebufotenin benzoate, a synthetic form of 5-MeO-DMT delivered as a nasal spray. Patients get it in a clinic setting and are monitored for about two hours, according to the companies' statement.

The drug targets treatment-resistant depression, a condition where standard antidepressants fail. The FDA has already granted BPL-003 Breakthrough Therapy Designation, and the drug has initiated Phase 3 activities. Initial Phase 3 results aren't expected until 2029, CNBC noted, meaning this is a long-term bet, not a quick payoff.

AtaiBeckley also has a second program, VLS-01, a buccal film formulation of DMT currently in an ongoing Phase 2b study, plus a broader pipeline of what the company calls "rapid-acting neuroplastogens." The company is also developing an MDMA-related compound.

The scientific premise, according to the companies' joint statement, is that treatment-resistant depression may stem from a loss of synaptic plasticity, the brain's ability to form and strengthen neural connections tied to mood regulation. Conventional antidepressants mainly target neurotransmitter levels like serotonin.

"Treatment-resistant depression persists even after multiple treatments have failed," said Carole Ho, executive vice president and president of Lilly Neuroscience. "Millions of people are still searching for relief and desperately need a therapy that works."

Srinivas Rao, co-founder and CEO of AtaiBeckley, framed the deal as validation of the company's underlying thesis: "Across our portfolio, we're seeking to demonstrate that psychiatric illness is treatable at its biological root, not just its symptoms."

Lilly's Buying Spree

Before announcing its intention to acquire AtaiBeckley, Lilly had already committed to spend more than $10 billion upfront — and potentially up to $25 billion total — across eight other acquisitions this year, according to CNBC. The AtaiBeckley deal adds to that run.

Lilly has become the world's most valuable healthcare company and is deliberately chasing later-stage, more expensive targets than it historically pursued, CNBC reported. That's a shift from buying cheap, early-stage biotech longshots to writing bigger checks for companies with drugs already deep into clinical trials, where the science is more proven but the price tag is steeper.

The Political Backdrop

CNBC's coverage notes the Trump administration has prioritized development of psychedelic-based treatments for conditions like depression and PTSD. That's a real shift in federal posture. For decades, DMT, psilocybin, and MDMA sat in the same legal bucket as heroin under the Controlled Substances Act, and government-funded research into their therapeutic use was nearly nonexistent.

The skeptical case here is straightforward: these are still Schedule I-adjacent compounds with a limited track record, administered under close clinical supervision, and the actual Phase 3 data proving durable, safe benefit at scale won't be in until 2029. A Breakthrough Therapy Designation from the FDA means the agency thinks the early data justifies an expedited review pathway. It is not the same as approval, and it's not proof the drug works for the broad population of patients who'd eventually use it.

That said, the Phase 2b results the companies cited showed rapid and durable reductions in depressive symptoms after an in-clinic visit lasting approximately two hours on average, with effects reportedly persisting for months, according to the joint statement. For a patient population defined by having already failed multiple standard treatments, that's a meaningfully different profile than daily-pill antidepressants that can take weeks to work and often don't work at all.

Neither CNBC nor the companies' statement addressed how Lilly plans to price or scale a treatment that requires a monitored, two-hour clinic visit. Insurers, clinics, and patients will eventually have to answer that question.

The transaction is not subject to any financing condition and is expected to close in the third quarter, subject to approval by AtaiBeckley stockholders and satisfaction of other customary closing conditions, including regulatory approvals, according to the companies' statement. Investors and clinicians alike will be watching for the Phase 3 data due in 2029 to see whether the premarket enthusiasm was warranted.